Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity

• Published in: Blood advances 2024-11, Vol.8 (21), p.5603-5611
• Main Authors: Shaffer, Brian C., Brown, Samantha, Chinapen, Stephanie, Mangold, Kathryn E., Lahoud, Oscar, Lopez-Jimenez, Francisco, Schaffer, Wendy, Liu, Jennifer, Giralt, Sergio, Devlin, Sean, Shah, Gunjan, Scordo, Michael, Papadopoulos, Esperanza, Landau, Heather, Usmani, Saad, Perales, Miguel-Angel, Friedman, Paul A., Gersh, Bernard J., Attia, Itzhak Zachi, Noseworthy, Peter A., Kosmidou, Ioanna
• Format: Article
• Language: English
• Subjects: Adult; Aged; Artificial Intelligence; Atrial Fibrillation - diagnosis; Electrocardiography; Female; Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Transplantation
• ISSN: 2473-9529; 2473-9537; 2473-9537
• DOI: 10.1182/bloodadvances.2024013636

•AI interpretation of pretransplant ECG images is a novel diagnostic tool to predict transplant arrhythmia risk.•AI-ECG prediction of AF also informed the risk of mortality after allo transplantation. [Display omitted] Artificial intelligence (AI)–enabled interpretation of electrocardiogram (ECG) images (AI-ECGs) can identify patterns predictive of future adverse cardiac events. We hypothesized that such an approach would provide prognostic information for the risk of cardiac complications and mortality in patients undergoing hematopoietic cell transplantation (HCT). We retrospectively subjected ECGs obtained before HCT to an externally trained, deep-learning model designed to predict the risk of atrial fibrillation (AF). Included were 1377 patients (849 autologous [auto] HCT and 528 allogeneic [allo] HCT recipients). The median follow-up was 2.9 years. The 3-year cumulative incidence of AF was 9% (95% confidence interval [CI], 7-12) in patients who underwent auto HCT and 13% (10%-16%) in patients who underwent allo HCT. In the entire cohort, pre-HCT AI-ECG estimate of AF risk correlated highly with the development of clinical AF (hazard ratio [HR], 7.37; 95% CI, 3.53-15.4; P < .001), inferior survival (HR, 2.4; 95% CI, 1.3-4.5; P = .004), and greater risk of nonrelapse mortality (NRM; HR, 95% CI, 3.36; 1.39-8.13; P = .007), without increased risk of relapse. Association with mortality was only noted in allo HCT recipients, where the risk of NRM was greater. The use of cyclophosphamide after transplantation resulted in greater 90-day incidence of AF (13% vs 5%; P = .01) compared to calcineurin inhibitor–based graft-versus-host disease prophylaxis, corresponding to temporal changes in AI-ECG AF prediction after HCT. In summary, AI-ECG can inform risk of posttransplant cardiac outcomes and survival in HCT patients and represents a novel strategy for personalized risk assessment.